SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 CLINICAL TRIAL FOR MR-301 IN SEVERE TBI PRINCETON ...
SHINKEI Therapeutics announced that the FDA has cleared its IND application for MR-101, a novel formulation candidate being developed for the treatment of Movement Disorders. The IND clearance allows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results